Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Chandan Healthcare share price today

CHANDANDiagnostic servicesConsolidatedPrices to 20 Nov 2026Results to Jun 2026

10Y not available: listed Feb 2025
Price, 200-day average and NIFTY 500Since Feb 2025Since Feb 2025

The price is 0.4% above its 200-day average and 23 points ahead of the NIFTY 500 since listing in Feb 2025

20 Nov 2026₹240.00Since listing in Feb 2025: Chandan Healthcare +38.4%, NIFTY 500 +15.7%
₹200₹300May 25Nov 25May 26Nov 26

Price growth

1Y3Y5Y10Y1Y−27.8%3YToo short5YToo short10YToo short

EPS and P/ESince Feb 2025Since Feb 2025

EPS ₹10.12, up 12% in a year; P/E 23.7

20 Nov 2026₹10.12 EPS
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Nov 26
₹0₹13

EPS growth

1Y3Y5Y10Y1Y+11.6%3YToo short5YToo short10YToo short

Revenue and marginsSince Feb 2025Insufficient history, from Mar 2022

Revenue up on a year for 3 quarters in a row; operating margin 24.2%, the highest on this chart

Jun 2026 quarter₹81 crore+19.1% on ₹68 crore a year earlier · NPM 9.8%
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
0₹100

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+20.0% to Mar3Y+26.3%/yr to Mar
Rev 5Y, Rev growth10YToo short
OPM average3Y17.4% to Mar5Y13.8% to Mar
NPM average3Y10.1% to Mar5Y7.6% to Mar

Return on capitalInsufficient history, from Mar 2023Insufficient history, from Mar 2023

ROCE was 22.3% for the year to Mar 2026, up from 15.7% in the year to Mar 2023

Year to Mar 202622.3% ROCEInsufficient history: data from Mar 2023
20%30%Mar 24Mar 25Mar 26

ROCE average

1Y3Y5Y10Y1Y22.3% to Mar3Y29.7% to Mar5YToo short10YToo short

Profit and cashSince Feb 2025Insufficient history, from Mar 2022

Cash from operations was 34% of profit over five years, 55% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹16 crore operating cashProfit ₹29 crore · Free cash −₹27 crore
FY22
FY23
FY24
FY25
FY26
₹50−₹50

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+20.8% to Mar3Y+113.0%/yr to Mar5YToo short10YToo short

ReinvestmentSince Feb 2025Insufficient history, from Mar 2022

Capex was ₹43 crore in the year to Mar 2026, 4.3 times depreciation

FY26₹43 crore capexWork in progress ₹12 crore
FY22
FY23
FY24
FY25
FY26
0₹50

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+10.0% to Mar3Y+100.5%/yr to Mar5YToo short10YToo short

BorrowingsInsufficient history, from Dec 2024Insufficient history, from Dec 2024

Debt ÷ equity 0.32 at 31 Mar 2026; profit covered interest 5.0x over the last four quarters

Mar 2026 balance sheet0.32 debt ÷ equityNet debt ₹38 crore
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
010x

Safety

Now3Y ago
Debt ÷ equity0.323Y ago0.78
Int. cover5.0x3Y ago3.5x

Operating healthSince Feb 2025Since Feb 2025

Working capital rose from -11 to 95 days since FY22

Year to Mar 202695 days working capital
0100Mar 23Mar 24Mar 25Mar 26
Working cap.951Y+453Y+1165YToo short
Debtor1141Y+393Y+515YToo short
Inventory1121Y−143Y+415YToo short

OwnershipInsufficient history, from Mar 2025Insufficient history, from Mar 2025

FIIs own 0.00%, down 1.11 points in a year. Promoters hold 48.42%

Share of the company held, %, by quarter end

Sep 2026 quarter0.00% FIIs
0%50%Sep 25Mar 26Sep 26

Change in holding, in points

FIIs1Y−1.113YToo short
Promoters1Y−1.053YToo short

Chandan Healthcare Ltd · CHANDAN · Diagnostic Services · price as of the 20 November 2026 close, updated every trading day · results updated weekly · research updated 18 August 2026

Chandan Healthcare share price today: ₹240.00 at the close on 20 November 2026, down 27.2% in a year. Chandan Healthcare (CHANDAN) is worth ₹586 crore, trades at a P/E of 23.7 and has closed between ₹199.80 and ₹338.10 over the past 52 weeks. Latest change: promoters cut their stake by 1.2 points in one quarter.

₹240.00Price −27.2% in a year
23.7×P/E lower than 66% of the last 1 year
₹80.8 CrRevenue (Jun 2026) +19.1% on a year ago
₹7.9 CrProfit (Jun 2026) +27.9% on a year ago
24.2%Operating margin +3.8 points on a year ago
22.3%ROCE year to Mar 2026
18.4%ROIC against a 12.0% cost of capital: +6.4 points
20%Profit that came in as cash last 3 years

Chandan Healthcare Ltd's earnings have grown faster than its share price. Earnings per share grew +11.6% in a year while the price moved −27.2%.

The main question: profits are rising, but only 20% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.

The price has been falling for 28 weeks, and the P/E is lower than 66% of its own last 1 year. Over the last four quarters, results have been improving, with profit +27.9% on a year earlier, and 20% of the last 3 years' profit came in as cash. What will decide it: whether the cash starts to follow the profit.

What is the Chandan Healthcare share price today?

Chandan Healthcare Ltd's share price was ₹240.00 at the close on 20 November 2026. It has been falling for 28 weeks. That is 0.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹200 and ₹338, and at that close it sat 29% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Chandan Healthcare Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Week by week since 2025: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 37 of 83 weeks

Week by week since 2025: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
21 Feb 2025no NIFTY 500 reading
28 Feb 2025no NIFTY 500 reading
7 Mar 2025no NIFTY 500 reading
13 Mar 2025no NIFTY 500 reading
21 Mar 2025no NIFTY 500 reading
28 Mar 2025no NIFTY 500 reading
4 Apr 2025no NIFTY 500 reading
11 Apr 2025no NIFTY 500 reading
17 Apr 2025no NIFTY 500 reading
25 Apr 2025no NIFTY 500 reading
2 May 2025no NIFTY 500 reading
9 May 2025no NIFTY 500 reading
16 May 2025no NIFTY 500 reading
23 May 2025−3.2%
30 May 2025+2.7%
6 Jun 2025−6.7%
13 Jun 2025+4.4%
20 Jun 2025−0.9%
27 Jun 2025−4.7%
4 Jul 2025−17.4%
11 Jul 2025−14.9%
18 Jul 2025−1.8%
25 Jul 2025+22.2%
1 Aug 2025+34.9%
8 Aug 2025+35.8%
14 Aug 2025+37.7%
22 Aug 2025+30.6%
29 Aug 2025+19.9%
5 Sep 2025+25.8%
12 Sep 2025+10.5%
19 Sep 2025+10.3%
26 Sep 2025+28.0%
3 Oct 2025+20.2%
10 Oct 2025+40.2%
17 Oct 2025+36.0%
24 Oct 2025+32.3%
31 Oct 2025+23.2%
7 Nov 2025+32.7%
14 Nov 2025+26.6%
21 Nov 2025+35.6%
28 Nov 2025+45.5%
5 Dec 2025+35.9%
12 Dec 2025+28.8%
19 Dec 2025+28.1%
26 Dec 2025+32.0%
2 Jan 2026+31.4%
9 Jan 2026+2.9%
16 Jan 2026−8.3%
23 Jan 2026−16.2%
1 Feb 2026−16.6%
6 Feb 2026−17.2%
13 Feb 2026−7.0%
20 Feb 2026−18.3%
27 Feb 2026−18.7%
6 Mar 2026−13.0%
13 Mar 2026−4.9%
20 Mar 2026−3.9%
27 Mar 2026−17.5%
17 Apr 2026−13.0%
24 Apr 2026−12.9%
30 Apr 2026−2.5%
8 May 2026−6.2%
15 May 2026−3.9%
22 May 2026−10.6%
29 May 2026−11.6%
4 Jun 2026−5.4%
5 Jun 2026−6.0%
10 Jun 2026−12.9%
12 Jun 2026−15.8%
17 Jun 2026−23.5%
19 Jun 2026−18.8%
24 Jun 2026−10.3%
25 Jun 2026−3.8%
1 Jul 2026+5.3%
3 Jul 2026−1.4%
10 Jul 2026−2.5%
17 Jul 2026−4.1%
24 Jul 2026−6.6%
31 Jul 2026−4.5%
7 Aug 2026−7.9%
14 Aug 2026+4.1%
21 Aug 2026−2.3%
28 Aug 2026+0.8%
4 Sep 2026−0.2%
11 Sep 2026−14.0%
18 Sep 2026−16.1%
25 Sep 2026−8.3%
1 Oct 2026−4.0%
9 Oct 2026+0.5%
16 Oct 2026+7.6%
23 Oct 2026+1.5%
30 Oct 2026+5.0%
6 Nov 2026+2.5%
8 Nov 2026−4.7%
13 Nov 2026+1.2%
20 Nov 2026+9.3%
Each bar is one week, from 2025 to now (83 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 1 year the share price moved +42% while the NIFTY 500 moved +15%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Chandan Healthcare this quarter?

8 points on a year earlier and number of shareholders up 29% in a year.

  1. Promoters cut their stake by 1.2 points in one quarter

    From 49.6% to 48.4% in the September 2026 quarter.

  2. Operating margin up 3.8 points on a year earlier

    24.2% in the June 2026 quarter, from 20.4%.

    Why: Management said the margin gain came from expanding the business and selling more.

    From the earnings call on 18 Aug 2026.

  3. Number of shareholders up 29% in a year

    1,688 shareholders in the September 2026 quarter, against 1,307 a year earlier.

What are Chandan Healthcare's latest quarterly results?

For April to June 2026 (the quarter ended 30 June 2026), Chandan Healthcare reported revenue of ₹80.8 crore, up 19.1% from ₹67.9 crore a year earlier, and a profit of ₹7.92 crore, up 27.9% from ₹6.19 crore.

Chandan Healthcare results: April to June 2026 against a year earlier

Chandan Healthcare results: April to June 2026 against a year earlier
MeasureApril to June 2026April to June 2025Change
Revenue₹80.8 crore₹67.9 crore+19.1%
Profit₹7.92 crore₹6.19 crore+27.9%
Earnings per share₹3.07₹2.37+29.5%
Operating margin24.2%20.4%+3.8 points

The next results, for July to September 2026, were due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them.

Chandan Healthcare's management discussed these results on a call held on 18 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

What is the Chandan Healthcare share price history?

Chandan Healthcare closed at ₹240.00 on 20 November 2026, down 27.2% from ₹329.70 a year earlier (21 November 2025). Its highest weekly close since February 2025 was ₹334.15 on 24 October 2025.

Chandan Healthcare share price: then and now

Chandan Healthcare share price: then and now
WhenCloseChange to 20 Nov 2026
1 week ago · 13 Nov 2026₹235.55+1.9%
1 month ago · 19 Oct 2026₹228.50+5.0%
6 months ago · 22 May 2026₹233.95+2.6%
1 year ago · 21 Nov 2025₹329.70−27.2%
Earliest weekly close in our records · 21 Feb 2025₹168.50+42.4%
Highest weekly close since February 2025 · 24 Oct 2025₹334.15−28.2%
Lowest weekly close since February 2025 · 28 Feb 2025₹157.55+52.3%
52-week high (weekly close) · 1 Dec 2025₹338.10−29.0%
52-week low (weekly close) · 11 Sep 2026₹199.80+20.1%

Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

96 weekly closes from 21 February 2025 to 20 November 2026.

What is the latest news on Chandan Healthcare?

20 Nov 2026: Chandan Healthcare closed at ₹240.00, up 1.9% on the week and up 5.0% on the month. 18 Aug 2026: Chandan Healthcare held its results call for April to June 2026. Management guided: Diagnostic topline growth above 50% year-on-year for the next 3 years.

Earlier

  • Results for April to June 2026: Revenue up 19.1% and profit up 27.9% on a year earlier.

What dividend does Chandan Healthcare pay?

Chandan Healthcare has paid no dividend on the exchange since its first close in our records (21 February 2025), the start of the period we checked.

No. Chandan Healthcare Ltd paid out 0% of its profit as dividends in each of its last 5 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the exchange corporate-actions record, read 20 November 2026.

What did Chandan Healthcare management say on the latest results call?

On the call for April to June 2026, held on 18 August 2026, Chandan Healthcare's management guided: Diagnostic topline growth above 50% year-on-year for the next 3 years.

“The way we are expanding our business, I am expecting more than 50% year-on-year growth for the next 3 years at the moment. Considering our plans and the way we are expanding throughout India, 50% will be a very achievable topline growth figure for the next 3 years.”Dr. Amar Singh, on the call for April to June 2026

What management guided

  • Diagnostic operating margin to reach 40% within a few months.
  • Franchise network above 1,000 in FY27 and 3,000 within 2 years.
  • Eight comprehensive centers and more than 6 laboratories to be operational within 3-4 months; 2 PET scan machines within 2-3 months; genome laboratory within 6 months.
  • Incremental FY27 capital spending of ₹10 crore or more, funded through internal accruals with debt available if required.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 18 August 2026.

What to watch in Chandan Healthcare's next results?

When Chandan Healthcare reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Franchise-driven sample volumes to begin scaling diagnostic revenue - check whether new collection centers contribute to reported growth.

Management raised each of these on the latest results call.

  • Franchise-driven sample volumes to begin scaling diagnostic revenue - check whether new collection centers contribute to reported growth.
  • Planned comprehensive centers, laboratories, PET, and genome capacity to commission on schedule - check opening dates and early utilization.
  • Government radiology rollout to advance as sites become available - check Punjab, Guwahati, and remaining locations.
  • B2G collections to remain contained despite ongoing projects - check receivable ageing and bad-debt disclosures.

Which stock lists is Chandan Healthcare on?

Chandan Healthcare is on one of our India lists: Healthcare & hospital stocks.

Is Chandan Healthcare profitable?

Chandan Healthcare Ltd earned ₹7.9 Cr of net profit in the Jun 2026 quarter, +27.9% on the same quarter a year earlier. Full-year FY26 profit was ₹29.0 Cr. The Jun 2026 quarter's profit is 9.8% of that quarter's revenue. The same quarter a year earlier earned ₹6.2 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹29.0 Cr (+20.8% on the year before).

Why profit moved: revenue changed +19.1% on a year earlier and the margin moved +3.8 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +6.0% and revenue +19.6%. Profit is growing slower than sales: rising costs are taking part of the growth.

How much revenue does Chandan Healthcare make, and is it growing?

Chandan Healthcare Ltd reported ₹80.8 Cr of revenue in the Jun 2026 quarter, +19.1% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 23.1% a year on average. The last full year, FY26, came in at ₹276 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹289 Cr.

FY26 revenue was ₹276 Cr, +20.0% on the year before.

Recent pace: the last four quarters grew +19.6% on average, against 23.1% a year over the longer run, so this year is growing slower than its own long-run rate.

How much of every ₹100 of sales does Chandan Healthcare keep?

Chandan Healthcare Ltd's operating margin was 24.2% in the Jun 2026 quarter, 3.8 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 1.7% and 19.2%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.8 percentage points on the year while gross margin changed +7.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Is Chandan Healthcare's profit turning into cash?

Over the last 3 years, 20% of Chandan Healthcare Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹16.0 Cr of operating cash against ₹29.0 Cr of profit. After ₹43.0 Cr of spending on assets, free cash was −₹27.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 20% of profit came in as cash: the cash cycle got 143 days longer between FY22 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 143 days longer. The next section looks at where the cash is stuck.

Where does Chandan Healthcare's cash go?

Chandan Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 92 days in FY26, up from −51 days in FY22. It spent ₹102 Cr on assets over the last 3 years. Customers take 114 days to pay, and stock sits for 112 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹276 Cr, each day of that cycle ties up about ₹0.8 Cr, so roughly ₹70.0 Cr is tied up in the business at any time.

FY26: customers took 114 days to pay and stock sat for 112 days, about 3.7 months of sales sitting as stock, for a full cycle of 92 days, longer than FY22's −51.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 112 days. Customers pay about 114 days after that. Suppliers are paid at 135 days. Together that makes the 92-day cycle.

Spending on assets: ₹102 Cr over the last 3 years, against ₹20.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹12.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

What is Chandan Healthcare's P/E ratio, and how does it compare with its own history?

Chandan Healthcare Ltd's P/E is 23.7×, near the low end of its own history: it has been lower only 34% of the time. Its usual P/E (the middle reading) is 25.3×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹10.12.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

23.7×P/E · lower than 66% of its last 1 year
n/mPEG · cannot be worked out, because 3-year earnings growth is not available

Why the multiple is where it is: over the past year earnings per share moved +11.6% while the price moved −27.2%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Is the Chandan Healthcare business getting better or worse?

Chandan Healthcare Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Steady highROCE · latest (year to Mar 2026) 22.3%, range 22.3% to 35.0%

Why it matters: with too little history, we say so rather than guess a direction.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+20.0%+26.3%——
Profit+20.8%+113.0%——
EPS+22.1%+87.5%——
Share price−27.8%———
+19.1%Revenue growth (Jun 2026) · latest quarter against a year ago
+27.9%Profit growth (Jun 2026) · latest quarter against a year ago
23.1%Revenue, 4 years · yearly growth over the long run

How much does Chandan Healthcare earn on its capital?

Chandan Healthcare Ltd earned a ROCE of 23% in FY26. That is up from a low of 16% in FY23. Its return on capital used (ROIC) is 6.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 10.5% net margin and 0.95× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 10.5% net margin × 0.95× asset turnover × 1.70× leverage (assets divided by equity) ≈ 17.0% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 18.4% − 12.0% = +6.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

Does Chandan Healthcare have too much debt?

Chandan Healthcare Ltd has total debt of ₹54.0 Cr against shareholder equity of ₹171 Cr as of Mar 2026, so its debt is 0.32× its equity. Year by year, that ratio went from 0.38 in FY25 to 0.31 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

What is the Chandan Healthcare shareholding pattern?

Foreign institutions cut their stake in Chandan Healthcare Ltd by 3.9 percentage points over 5 quarters, the biggest change among its owners. Foreign institutions now own 0.0% of the company. Domestic institutions moved −1.3 points over the same period, to 5.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: −3.9 points over 5 quarters, to 0.0%; Domestic institutions: −1.3 points over 5 quarters, to 5.1%; Promoters: −1.0 points over 5 quarters, to 48.4%.

Why the owners changed: foreign institutions drove it (−3.9 points), together with domestic institutions (−1.3 points). They reduced their stake.

How far is Chandan Healthcare from balance-sheet trouble?

For Chandan Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Chandan Healthcare rank in its industry?

61.2 out of 100, rank 2 of 3 in Diagnostic Services, with 61% of the evidence available.

Chandan Healthcare Ltd scores 61.2 out of 100 against the 3 companies it is compared with in Diagnostic Services, ranking 2. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 21.7 + 22 + 10 + 7.5 = 61.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Chandan Healthcare compared with?

Chandan Healthcare ranks 2 of 3 Diagnostic Services companies on the 4-Factor Sector Score, with 61.2 out of 100.

  1. 1Dr Lal Pathlabs LtdEvidence leans up · 62% evidence62.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 16.3/35 · Revenue 14.3% · Profit 5% · Operating margin change 1 points · 95% evidenceCapital efficiency 23.4/25 · ROCE 28% (year to Mar 2026) · Operating margin 32% · 95% evidenceValuation 10.0/20 · P/E 57.5× · PEG — · 0% evidenceRelative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 21.3% · 1 year — · 25% evidence · 6 of 6 weeks aheadExact sum: 16.3 + 23.4 + 10 + 12.5 = 62.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Chandan Healthcare Ltd this pageCHANDAN · quiet · Evidence leans up · 61% evidence61.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.7/35 · Revenue 20% · Profit 17.7% · Operating margin change 3.8 points · 88% evidenceCapital efficiency 22.0/25 · ROCE 23.3% (year to Mar 2026) · Operating margin 24.2% · 100% evidenceValuation 10.0/20 · P/E 23.7× · PEG — · 0% evidenceRelative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -10.1% · 1 year -27.2% · 25% evidence · 1 of 12 weeks aheadExact sum: 21.7 + 22 + 10 + 7.5 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 33B Blackbio DX LtdEvidence leans up · 65% evidence57.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 18.6/35 · Revenue 33.3% · Profit 20.8% · Operating margin change -27.8 points · 83% evidenceCapital efficiency 21.5/25 · ROCE 25.5% (year to Mar 2026) · Operating margin 25.4% · 95% evidenceValuation 10.0/20 · P/E 20.2× · PEG — · 35% evidenceRelative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -5.7% · 1 year 1.8% · 25% evidence · 7 of 12 weeks aheadExact sum: 18.6 + 21.5 + 10 + 7.5 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Diagnostic Services, all 3 compared on one page.

Which companies are close to Chandan Healthcare in size?

Chandan Healthcare is the 3rd largest of 3 Diagnostic Services companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Dr Lal Pathlabs and 3B Blackbio DX. It is the smallest.

Diagnostic Services companies close in size

  1. Dr Lal Pathlabs Ltd ₹33,690 crore
  2. 3B Blackbio DX Ltd ₹1,124 crore
  3. Chandan Healthcare Ltd ₹586 crore

All 3 Diagnostic Services companies, largest first

Companies close in size in other industries

  1. Mangalam Global Enterprise Ltd ₹587 crore · Trading
  2. Aryaman Capital Markets Ltd ₹586 crore · Finance - Investment/Others
  3. Chandan Healthcare Ltd ₹586 crore
  4. Allied Digital Services Ltd ₹586 crore · IT - Software
  5. Innovision Ltd ₹585 crore

What else do people ask about Chandan Healthcare?

What were Chandan Healthcare's latest quarterly results?

Chandan Healthcare Ltd reported revenue of ₹80.8 Cr and net profit of ₹7.9 Cr for the Jun 2026 quarter. Revenue rose 19.1% and profit rose 27.9% compared with a year earlier. Earnings per share were ₹3.07.

The operating margin was 24.2%, 3.8 percentage points higher than a year earlier (as of 20 November 2026).

What is Chandan Healthcare's market cap?

Chandan Healthcare Ltd's market capitalisation is ₹586 Cr at a share price of ₹240.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026).

How is Chandan Healthcare performing?

Chandan Healthcare Ltd's share price has been falling for 28 weeks. In its latest quarter, revenue rose 19.1% and profit rose 27.9% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 20 November 2026).

Will Chandan Healthcare's share price go up?

This page does not forecast Chandan Healthcare Ltd's share price. What it shows instead: the share price is ₹240.00, and it has been falling for 28 weeks. Its P/E of 23.7× is higher than 34% of its own last 2 years (as of 20 November 2026).

Who owns Chandan Healthcare?

Promoters own 48.4% of Chandan Healthcare Ltd, foreign institutions 0.0%, domestic institutions 5.1% and the public 46.5% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 3.9 percentage points over 5 quarters (as of 20 November 2026).

Where is Chandan Healthcare in its business cycle?

Chandan Healthcare Ltd's FY26 operating margin was 19.2%, against a 5-year range of 1.7% to 19.2%. The latest quarter was 24.2%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026).

What could break the Chandan Healthcare story?

The main question: profits are rising, but only 20% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026).

Is Chandan Healthcare a stock worth studying right now?

What the numbers show: Chandan Healthcare Ltd's earnings have grown faster than its share price. Earnings per share grew +11.6% in a year while the price moved −27.2%. The main open question: whether the cash starts to follow the profit.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026).

Is there a Chandan Healthcare share price forecast for 2026?

What management itself guided: Diagnostic topline growth above 50% year-on-year for the next 3 years.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 20 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.